Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Cash & Equivalents (2018 - 2026)

TELA Bio has reported Cash & Equivalents over the past 8 years, most recently at $50.8 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 3.46% year-over-year to $50.8 million; the TTM value through Dec 2025 reached $50.8 million, down 3.46%, while the annual FY2025 figure was $50.8 million, 3.46% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $50.8 million at TELA Bio, up from $29.7 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $65.8 million in Q1 2021 and troughed at $17.3 million in Q3 2024.
  • A 5-year average of $43.6 million and a median of $43.4 million in 2021 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: soared 135.4% in 2023 and later plummeted 70.27% in 2024.
  • Year by year, Cash & Equivalents stood at $43.9 million in 2021, then decreased by 4.35% to $42.0 million in 2022, then rose by 11.21% to $46.7 million in 2023, then increased by 12.71% to $52.7 million in 2024, then dropped by 3.46% to $50.8 million in 2025.
  • Business Quant data shows Cash & Equivalents for TELA at $50.8 million in Q4 2025, $29.7 million in Q3 2025, and $35.0 million in Q2 2025.